News

Watson has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its guaifenesin pseudoephedrine HCI extended-release 600mg/60mg and 1200mg/120mg tablets prior to the

nCircle and Health Information Trust Alliance (HITRUST) have announced that nCircle has been selected as the provider of vulnerability and configuration assessments as a service for the HITRUST

PharmaSURVEYOR has announced the integration of their Advanced Drug Safety service with Microsoft HealthVault. The tool is designed to show users not only drug-drug interactions but also the

MonoSol Rx, the developers of PharmFilm technology and a drug delivery company has announced that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has

Access Pharmaceuticals has announced that the company has received issue notifications from the US Patent and Trademark Office that two US patents relating to MuGard, the company’s approved

NeurogesX has announced that FDA agreed to its proposed study to evaluate Qutenza in patients with post-herpetic neuralgia (PHN) following pretreatment with an FDA approved topical anesthetic.  

Roche has reported that up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA for over two years, will achieve disease remission. The new data

Roche has announced one year data from the two year Phase III LITHE study. The study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with

Altus has initiated patient dosing in phase-II trial for ALTU-238 in growth hormone deficiency pediatric subjects. ALTU-238 is a long-acting, extended release formulation of recombinant human growth hormone.